ArticleInvestigational new drugs2025
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells.
Arianna Bandini et al.PubMed ↗Publisher ↗
No numbers read from the abstract.